Background:Traditional chemotherapy regimens are not ideal for the treatment of peripheral T-cell lymphoma(PTCL). Recent clinical data have shown Chidamide,a type of histone deacetylase inhibitors, as a new type of anti-tumor drug, have achieved remarkable results in the treatment of PTCL.Therefore, we performed a systematic literature review and meta-analysis to objectively assess the efficacy and safety for peripheral T-cell lymphoma treated with Chidamide alone or Chidamide combination with chemotherapy. Methods:We searched systematically for studies from the databases of PubMed, Embase, and the Cochrane Library published were searched without language restriction from inception until June 2022.using the following combination of free-text terms linked by Boolean operators: “peripheral T-cell lymphoma”OR“PTCL”OR“angioimmunoblastic lymphoma”OR“anaplastic large cell lymphoma”OR“NK/T-cell lymphoma”AND“Chidamide”. The primary end points were complete remission and overall response rates, adverse events were the secondary end points. Results: A total of 7 clinical trials including newly-diagnosed and relapsed or refractory PTCL patients were analyzed.The overall CR rate was 35.2%(95% CI, 24.2-48%, Figure 2). And the ORR was 65.8%(95% CI, 54.4-75.6%). Thrombocytopenia, anemia, neutropenia were the most common grade 3 and 4 AEs. Conclusion: Chidamide is effective for PTCL, and its efficacy can be increased with the combination traditional chemotherapy.